This work is licensed under the Creative Commons Attribution 4.0 International License.
Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: An evidence-based review. Crit Care Med. 2004;32(11 SUPPL.):455–65.BealeRJHollenbergSMVincentJLParrilloJEVasopressor and inotropic support in septic shock: An evidence-based review20043211 SUPPL4556510.1097/01.CCM.0000142909.86238.B115542956Search in Google Scholar
ICNARC. Key statistics from the Case Mix Programme — adult , general critical care units Critical care units in the Case Mix Programme. Case Mix Program Summ Stat 2018 -19 [Internet]. 2019;(March 2019):1–11. Available from: htps://www.icnarc.org/Our-Audit/Audits/Cmp/Reports/Summary-Statistics2019(March 2019)1–11Available fromhtps://www.icnarc.org/Our-Audit/Audits/Cmp/Reports/Summary-StatisticsSearch in Google Scholar
NHS. Critical Care Minimum Dataset Full Specification [Internet]. 2010. Available from: htps://www.datadictionary.nhs.uk/data_sets/supporting_data_sets/critical_care_minimum_data_set.html2010Available fromhtps://www.datadictionary.nhs.uk/data_sets/supporting_data_sets/critical_care_minimum_data_set.htmlSearch in Google Scholar
Gamper G, Havel C, Arrich J, Losert H, Pace NL, Müllner M, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016 Feb 15;61(3):351–2.GamperGHavelCArrichJLosertHPaceNLMüllnerMet alVasopressors for hypotensive shock15613351210.1002/14651858.CD003709.pub4651685626878401Search in Google Scholar
Holmesa CL, Walley KR. Vasoactive drugs for vasodilatory shock in ICU. Curr Opin Crit Care. 2009;15(5):398–402.HolmesaCLWalleyKRVasoactive drugs for vasodilatory shock in ICU200915539840210.1097/MCC.0b013e32832e96ef19542884Search in Google Scholar
Laterre PF, Berry SM, Blemings A, Carlsen JE, François B, Graves T, et al. Effect of Selepressin vs Placebo on Ventilator-and Vasopressor-Free Days in Patients with Septic Shock: The SEPSIS-ACT Randomized Clinical Trial. JAMA - J Am Med Assoc. 2019;322(15):1476–85.LaterrePFBerrySMBlemingsACarlsenJEFrançoisBGravesTet alEffect of Selepressin vs Placebo on Ventilator-and Vasopressor-Free Days in Patients with Septic Shock: The SEPSIS-ACT Randomized Clinical Trial20193221514768510.1001/jama.2019.14607680226031577035Search in Google Scholar
Guinot PG, Martin A, Berthoud V, Voizeux P, Bartamian L, Santangelo E, et al. Vasopressor-sparing strategies in patients with shock: A scoping-review and an evidence-based strategy proposition. J Clin Med. 2021;10(14).GuinotPGMartinABerthoudVVoizeuxPBartamianLSantangeloEet alVasopressor-sparing strategies in patients with shock: A scoping-review and an evidence-based strategy proposition2021101410.3390/jcm10143164830639634300330Search in Google Scholar
Scheeren TWL, Bakker J, De Backer D, Annane D, Asfar P, Boerma EC, et al. Current use of vasopressors in septic shock. Ann Intensive Care [Internet]. 2019;9(1):1–12.ScheerenTWLBakkerJDe BackerDAnnaneDAsfarPBoermaECet alCurrent use of vasopressors in septic shock20199111210.1186/s13613-019-0498-7635397730701448Search in Google Scholar
Hamzaoui O, Scheeren TWL, Teboul JL. Norepinephrine in septic shock: When and how much? Curr Opin Crit Care. 2017;23(4):342–7.HamzaouiOScheerenTWLTeboulJLNorepinephrine in septic shock: When and how much?2017234342710.1097/MCC.000000000000041828509668Search in Google Scholar
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Critical Care Medicine. 2017;45:486–552.RhodesAEvansLEAlhazzaniWLevyMMAntonelliMFerrerRet alSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 201620174548655210.1007/s00134-017-4683-628101605Search in Google Scholar
Møller MH, Claudius C, Juntila E, Haney M, Oscarsson-Tibblin A, Haavind A, et al. Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure. Acta Anaesthesiol Scand. 2016;60(10):1347– 66.MøllerMHClaudiusCJuntilaEHaneyMOscarsson-TibblinAHaavindAet alScandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failure201660101347–6610.1111/aas.12780521373827576362Search in Google Scholar
Oba Y, Lone NA. Mortality benefit of vasopressor and inotropic agents in septic shock: A Bayesian network meta-analysis of randomized controlled trials. J Crit Care. 2014;29(5):706–10.ObaYLoneNAMortality benefit of vasopressor and inotropic agents in septic shock: A Bayesian network meta-analysis of randomized controlled trials20142957061010.1016/j.jcrc.2014.04.01124857641Search in Google Scholar
Lamontagne F, Richards-Belle A, Thomas K, Harrison DA, Sadique MZ, Grieve RD, et al. Efect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients with Vasodilatory Hypotension: A Randomized Clinical Trial. JAMA -J Am Med Assoc. 2020;323(10):938–49.LamontagneFRichards-BelleAThomasKHarrisonDASadiqueMZGrieveRDet alEfect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients with Vasodilatory Hypotension: A Randomized Clinical Trial2020323109384910.1001/jama.2020.0930706488032049269Search in Google Scholar
BNF. NOREPINEPHRINE | Drug | BNF content published by NICE [Internet]. [cited 2022 Mar 19]. Available from: htps://bnf.nice.org.uk/drug/noradrenalinenorepinephrine.html[cited 2022 Mar 19]. Available fromhtps://bnf.nice.org.uk/drug/noradrenalinenorepinephrine.htmlSearch in Google Scholar
BNF. METARAMINOL | Drug | BNF content published by NICE [Internet]. [cited 2022 Mar 19]. Available from: htps://bnf.nice.org.uk/drug/metaraminol.html[cited 2022 Mar 19]. Available fromhtps://bnf.nice.org.uk/drug/metaraminol.htmlSearch in Google Scholar
SHPA. Australian Injectable Drugs Handbook, 8th edition [Internet]. 2022 [cited 2022 Mar 19]. Available from: htps://aidh.hcn.com.au/login2022[cited 2022 Mar 19]. Available fromhtps://aidh.hcn.com.au/loginSearch in Google Scholar
Kelly FE, Fong K, Hirsch N, Nolan JP. Intensive care medicine is 60 years old: The history and future of the intensive care unit. Clin Med J R Coll Physicians London. 2014;14(4):376–9.KellyFEFongKHirschNNolanJPIntensive care medicine is 60 years old: The history and future of the intensive care unit2014144376910.7861/clinmedicine.14-4-376495283025099838Search in Google Scholar
Vincent JL. Critical care--where have we been and where are we going? Crit Care. 2013;17 Suppl 1(Suppl 1):1–6.VincentJLCritical care--where have we been and where are we going?201317 Suppl1Suppl 11610.1186/cc11500360347923514264Search in Google Scholar
PRISMA. PRISMA Protocols [Internet]. 2015. Available from: htp://prisma-statement.org/Protocols/2015Available fromhtp://prisma-statement.org/Protocols/Search in Google Scholar
Define - RX-Info [Internet]. Available from: htp://www.rx-info.co.uk/products/define.ashxAvailable fromhtp://www.rx-info.co.uk/products/define.ashxSearch in Google Scholar
Sardaneh AA, Penm J, Oliver M, Gatas D, McLachlan AJ, Patanwala AE. Pharmacoepidemiology of metaraminol in critically ill patients with shock in a tertiary care hospital. Aust Crit Care [Internet]. 2021;34(6):573–9.SardanehAAPenmJOliverMGatasDMcLachlanAJPatanwalaAEPharmacoepidemiology of metaraminol in critically ill patients with shock in a tertiary care hospital2021346573910.1016/j.aucc.2021.01.00233663948Search in Google Scholar
Da Silva PS, Furtado P. Methylene Blue to Treat Refractory Latex-Induced Anaphylactic Shock. A A Pract. 2018;10(3):57–60.DaSilva PSFurtadoPMethylene Blue to Treat Refractory Latex-Induced Anaphylactic Shock2018103576010.1213/XAA.000000000000063028937421Search in Google Scholar
Abu Sardaneh A, Penm J, Oliver M, Gattas D, Mclachlan A, Patanwala A. Comparison of metaraminol versus no metaraminol on time to resolution of shock in critically ill patients. Eur J Hosp Pharm [Internet]. 2021 Oct 7;ejhpharm-2021-003035.AbuSardaneh APenmJOliverMGattasDMclachlanAPatanwalaAComparison of metaraminol versus no metaraminol on time to resolution of shock in critically ill patients2021Oct 7;ejhpharm-2021-00303510.1136/ejhpharm-2021-00303534620686Search in Google Scholar
Hou LC, Li SZ, Xiong LZ, Chen SY, Chen M, Zhang XJ, et al. Efect of dopamine and metaraminol on the renal function of patients with septic shock. Chin Med J (Engl). 2007;120(8):680–3.HouLCLiSZXiongLZChenSYChenMZhangXJet alEfect of dopamine and metaraminol on the renal function of patients with septic shock20071208680310.1097/00029330-200704020-00013Search in Google Scholar
Anderson AK, Chatha H. Best evidence topic reports sepsis resulting in persistent hypotension Search outcomes BET 3 : Peripheral metaraminol infusion in the emergency department contained no relevant evidence or guide. Best evidence topic reports. 2017;34(3).AndersonAKChathaHBest evidence topic reports sepsis resulting in persistent hypotension Search outcomes BET 3 : Peripheral metaraminol infusion in the emergency department contained no relevant evidence or guide201734310.1136/emermed-2017-206590.3550223528232631Search in Google Scholar
Hayward MD, Regan L, Glasheen J, Burns B. Review of therapeutic agents employed by an Australian aeromedical prehospital and retrieval service. EMA - Emerg Med Australas. 2016;28(3):329–34.HaywardMDReganLGlasheenJBurnsBReview of therapeutic agents employed by an Australian aeromedical prehospital and retrieval service20162833293410.1111/1742-6723.1258427250671Search in Google Scholar
Redmond M, Knapp C, Salim M, Shanbhag S, Jaumdally R. Use of vasopressors in Takotsubo cardiomyopathy: A cautionary tale. Br J Anaesth. 2013;110(3):487–8.RedmondMKnappCSalimMShanbhagSJaumdallyRUse of vasopressors in Takotsubo cardiomyopathy: A cautionary tale20131103487810.1093/bja/aes58623404978Search in Google Scholar
Isbister GK, Duffull SB. Quetiapine overdose: Predicting intubation, duration of ventilation, cardiac monitoring and the effect of activated charcoal. Int Clin Psychopharmacol. 2009;24(4):174–80.IsbisterGKDuffullSBQuetiapine overdose: Predicting intubation, duration of ventilation, cardiac monitoring and the effect of activated charcoal20092441748010.1097/YIC.0b013e32832bb07819494786Search in Google Scholar
Dewachter P, Mouton-Faivre C, Emala CW, Riou B. Anaphylaxis and Anesthesia. Anesthesiology. 2009 Nov 1;111(5):1141–50.DewachterPMouton-FaivreCEmalaCWRiouBAnaphylaxis and Anesthesia2009Nov 1111511415010.1097/ALN.0b013e3181bbd44319858877Search in Google Scholar
Brown SG. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol. 2005 Aug;5(4):359–64.BrownSGCardiovascular aspects of anaphylaxis: implications for treatment and diagnosis2005Aug;543596410.1097/01.all.0000174158.78626.3515985820Search in Google Scholar
Wood DM, Wright KD, Jones AL, Dargan PI. Metaraminol (Aramine®) in the management of a significant amlodipine overdose. Hum Exp Toxicol. 2005;24(7):377–81.WoodDMWrightKDJonesALDarganPIMetaraminol (Aramine®) in the management of a significant amlodipine overdose20052473778110.1191/0960327105ht538oa16119252Search in Google Scholar
Holmes CL. Vasoactive drugs in the intensive care unit. Curr Opin Crit Care. 2005;11(5):413–7.HolmesCLVasoactive drugs in the intensive care unit2005115413710.1097/01.ccx.0000176696.70013.da16175026Search in Google Scholar
Ruchti VEW, Wibrow BA, Seet J, Jacques A, Jha N, Anstey MH. A prospective comparison of peripheral metaraminol versus dilute noradrenaline in the intensive care unit. Anaesth Intensive Care. 2021;49(2):144–6.RuchtiVEWWibrowBASeetJJacquesAJhaNAnsteyMHA prospective comparison of peripheral metaraminol versus dilute noradrenaline in the intensive care unit2021492144610.1177/0310057X2098479433853391Search in Google Scholar
Abu Sardaneh A, Goradia S, Narayan SW, Penm J, McLachlan AJ, Patanwala AE. Dose equivalence between metaraminol and norepinephrine in critical care. Br J Clin Pharmacol. 2021;(May):1–8.AbuSardaneh AGoradiaSNarayanSWPenmJMcLachlanAJPatanwalaAEDose equivalence between metaraminol and norepinephrine in critical care20211–810.1111/bcp.1496934197654Search in Google Scholar
Natalini G, Schivalocchi V, Rosano A, Taranto M, Pletti C, Bernardini A. Norepinephrine and metaraminol in septic shock: A comparison of the hemodynamic effects. Intensive Care Med. 2005;31(5):634–7.NataliniGSchivalocchiVRosanoATarantoMPlettiCBernardiniANorepinephrine and metaraminol in septic shock: A comparison of the hemodynamic effects2005315634710.1007/s00134-005-2607-315803299Search in Google Scholar
Weiniger CF, Firman S. Drugs in Anaesthesia and Intensive Care, 5th Ed. Anesth Analg. 2017;124(2):691.WeinigerCFFirmanSDrugs in Anaesthesia and Intensive Care, 5th Ed2017124269110.1213/ANE.0000000000001752Search in Google Scholar
De Backer D. Detailing the cardiovascular profile in shock patients. Crit Care. 2017;21(Suppl 3):311.DeBacker DDetailing the cardiovascular profile in shock patients201721Suppl 331110.1186/s13054-017-1908-6575163729297372Search in Google Scholar
Bonanno FG. Physiopathology of shock. J Emergencies, Trauma Shock. 2011;4(2):222–32.BonannoFGPhysiopathology of shock2011422223210.4103/0974-2700.82210313236321769210Search in Google Scholar
Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubenfeld G, Wunsch H. Association between US norepinephrine shortage and mortality among patients with septic shock. JAMA - J Am Med Assoc. 2017;317(14):1433–42.VailEGershengornHBHuaMWalkeyAJRubenfeldGWunschHAssociation between US norepinephrine shortage and mortality among patients with septic shock20173171414334210.1001/jama.2017.284128322415Search in Google Scholar